Latest news and press releases about IN8bio, Inc. (INAB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
Price
| Price | $1.01 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · APRE · APVO · BCDA · GLTO · HCWB · KPRX
Explore sector: Healthcare · Biotechnology
More sections of INAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks